Pfizer
NEWS
Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
Data presented at the virtual American Diabetes Association meeting has Pfizer excited about the promise of its GLP-1R Agonist PF-06882961.
Results from the Phase III JADE TEEN study of abrocitinib in teen patients, ages 12 to 18, who have moderate to severe atopic dermatitis and were on background topical therapy, showed improvements in skin clearance, disease extent and a reduction in severity.
Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration has narrowed that list even more to five potential treatments for the prevention of the novel coronavirus.
Pfizer has its eye on supporting innovation in the biotech industry to support small and medium-sized companies working in indications that fall under Pfizer’s core areas of focus.
Pfizer shared results from the trial on Friday, and the data determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival in patients with breast cancer.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
The therapy demonstrated durable and statistically significant improvements in a number of efficacy endpoints measured 12 months after infusion.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
JOBS
IN THE PRESS